Sign In
Buy ADMA
$8.69
+0.120 (+1.40%)
At Close: Jun 23, 2026
Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns?
01:56pm, Thursday, 16'th Apr 2026
ADMA stock slides after a short report sparks volatility, but management pushes back, citing strong Asceniv demand and steady fundamentals.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
10:00am, Thursday, 16'th Apr 2026
NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to co
ADMA Biologics Inc (NASDAQ:ADMA) Receives $28.00 Consensus Price Target from Analysts
01:11am, Thursday, 16'th Apr 2026
Shares of ADMA Biologics Inc (NASDAQ: ADMA - Get Free Report) have been assigned a consensus recommendation of "Buy" from the five ratings firms that are covering the company, MarketBeat reports. Two
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
06:50pm, Wednesday, 15'th Apr 2026
Adma Biologics (ADMA) reached $10.65 at the closing of the latest trading day, reflecting a +1.53% change compared to its last close.
ADMA Crashes 42.5% YTD: Right Time to Buy the Stock?
04:01pm, Wednesday, 15'th Apr 2026
ADMA stock plunges after a short report, but strong Asceniv demand, rising revenues, and margin expansion signal potential recovery ahead.
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
01:30pm, Wednesday, 15'th Apr 2026
NEW YORK, April 15, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ADMA Biologics,
ADMA Biologics guided 2026 revenue to at least $635 million -- built on a 2025 revenue base a short-seller report alleges was inflated by as much as 23 percentage points. NEW YORK, April 15, 2026 /PRN
NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the
SAN FRANCISCO, April 14, 2026 /PRNewswire/ -- Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) saw the price of their shares slide over 16% on March 24, 2026 on short seller Culper Research's report,
NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the f
ADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
03:48pm, Friday, 10'th Apr 2026
NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C. , a top complex litigation law firm, is investigating ADMA Biologics (NASDAQ: ADMA) (“ADMA Biologics” or the “Company”) for p
Is ADMA Poised for Margin Growth and Supply Expansion in 2026?
11:00am, Friday, 10'th Apr 2026
ADMA rides on margin gains, supply deals, and IVIG shift into 2026, but valuation and recent stock decline add complexity for investors.
NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the f
Adma Biologics (ADMA) Laps the Stock Market: Here's Why
06:50pm, Thursday, 09'th Apr 2026
Adma Biologics (ADMA) concluded the recent trading session at $9.95, signifying a +1.22% move from its prior day's close.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
10:00am, Thursday, 09'th Apr 2026
NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to con
